Janssen Pharmaceutica Nv

Janssen-Cilag S.a.

Janssen-Cilag

Francisco Javier Fernandez-Gadea

Pedro Martinez-Jimenez

Manuel Jesus Alcazar-Vaca

Antonio Gomez-Sanchez

Jose Manuel Bartolome-Nebreda

Frank Tegtmeier

Jozef Leo Henri Van Reempts

Joseph Elisabeth Leenaerts

Frans Eduard Janssens

Koenraad Arthur Van Rossem

Frans E Janssens

José Manuel Bartolomé-Nebreda

Francisco Javier Fernández-Gadea

Manuel Jesús Alcázar-Vaca

Antonio Gómez-Sánchez

Pedro Martínez-Jiménez

The invention concerns a novel histamine receptor antagonist and the use of an histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemida, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise compounds according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-&#x3b1;]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. Also claimed is the novel use of commercially available histamine H1-and H2-receptor antagonists for the reduction of intracranial pressure (ICP). 

Use of anti-histaminics for acute reduction of elevated intracranial pressure

Growing community of inventors

Geel, Belgium

Jozef Leo Henri Van Reempts